Catalyst Biosciences Announces Chief Financial Officer Transition
October 13 2021 - 4:05PM
Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that its
chief financial officer, Clinton Musil, has resigned for
personal reasons effective October 29, 2021. Seline Miller, the
Company’s controller, has been promoted to senior vice president,
finance and will serve as interim chief financial and principal
accounting officer while the Company initiates a search for a
successor.
“I would like to thank Clinton for his many contributions as a
member of our executive leadership team as we advance several
programs in our Protease Medicines platform,” said Nassim Usman,
Ph.D., chief executive officer of Catalyst. “We wish Clinton the
best in his next endeavor.”
Mr. Musil added, “I am proud to have been part of advancing
Catalyst’s Protease Medicines programs and I look forward to
following the Company’s progress in the years ahead. I’d like to
say thank you to all my fellow employees for their hard work and
dedication to the Company’s mission.”
About Catalyst Biosciences, the Protease Medicines
companyCatalyst is a research and clinical development
biopharmaceutical company focused on addressing unmet medical needs
in rare disorders of the complement and coagulation systems. Our
protease engineering platform has generated two late-stage clinical
programs, including MarzAA, a subcutaneously (SQ) administered
next-generation engineered coagulation Factor VIIa (FVIIa) for the
treatment of episodic bleeding in subjects with rare bleeding
disorders. Our complement pipeline includes a preclinical
C3-degrader program licensed to Biogen for dry age-related macular
degeneration, an improved complement factor I protease for SQ
replacement therapy in patients with CFI deficiency and proteases
from our ProTUNE™ C3b-C4b degrader and ImmunoTUNE™ C3a-C5a degrader
platforms designed to target specific disorders of the complement
or inflammatory pathways as well as other complement programs in
development.
Forward-Looking StatementsThis press release
contains forward-looking statements that involve substantial risks
and uncertainties. Forward-looking statements include, without
limitation, statements about the product candidates
of Catalyst Biosciences, Inc. (the “Company”) and the
benefits of its protease engineering platform. Actual results or
events could differ materially from the plans, intentions,
expectations and projections disclosed in the forward-looking
statements. Various important factors could cause actual results or
events to differ materially, including, but not limited to, the
risk that clinical trials and pre-clinical studies may be delayed
as a result of COVID-19, competitive products and other factors,
that clinical trials may not have satisfactory outcomes, that the
Company’s complement degraders are not yet in human clinical trials
and will require additional manufacturing validation and
pre-clinical testing before entering human clinical trials, that
the Company may need to raise additional capital, and other risks
described in the "Risk Factors" section of the Company's Annual
Report on Form 10-K filed with the Securities and Exchange
Commission (the “SEC”) on March 4, 2021, the Quarterly Report
on Form 10-Q filed with the SEC on August 5, 2021, and in
other filings filed from time to time with the SEC. The
Company does not assume any obligation to update any
forward-looking statements, except as required by law.
Contact:Ana KaporCatalyst Biosciences,
Inc.investors@catbio.com
Catalyst Biosciences (NASDAQ:CBIO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Catalyst Biosciences (NASDAQ:CBIO)
Historical Stock Chart
From Sep 2023 to Sep 2024